BN Business News
Додати компанію →
Цей переклад готується. Тимчасово ми показуємо оригінальну версію англійською мовою.

Бізнес · 08.08.20111 хв читання

Prospective Grant of Exclusive License: Use of PKM2 Activators for the Treatment of Cancer

Локальний автоматичний переклад · Оригінальна мова джерела

Короткий зміст

This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in U.S. Provisional Patent Application No. 61/104,091, entitled "Activators of Human Pyruvate Kinase," filed October 9, 2008, now abandoned [HHS Ref. No. E-326-2008/0-US-01]; PCT/US2009/60237 Application entitled "Small Molecule Activators of Pyruvate Kinase," filed October 9, 2009, now abandoned [HHS Ref. No. E-326-2008/0-PCT-02]; EP Application No. 09740795.1, entitled "Small Molecule Activators of Pyruvate Kinase," filed October 9, 2009 [HHS Ref. No. E-326-2008/0-EP-05]; U.S. Non- Provisional Application No. 13/123,297, entitled "Small Molecule Activators of Pyruvate Kinase," filed April 8, 2011 [HHS Ref. No. E-326-2008/0-US-07]; Australian National Application No. 2009303335, entitled "Small Molecule Activators of Pyruvate Kinase," filed October 9, 2010 [HHS Ref. No. E-326-2008/0-AU-03]; Canadian National Application, entitled "Small Molecule Activators of Pyruvate Kinase," filing date pending [HHS Ref. No. E-326-2008/0-CA-04

Оригінальна мова джерела: Federal Register — Health and Human ServicesВідкрити оригінальне повідомлення →

Інші тематичні добірки

Ділова аналітика →